Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria
Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States,...
Gespeichert in:
| Veröffentlicht in: | The American journal of tropical medicine and hygiene 2017-09, Vol.97 (3), p.677-680 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 680 |
|---|---|
| container_issue | 3 |
| container_start_page | 677 |
| container_title | The American journal of tropical medicine and hygiene |
| container_volume | 97 |
| creator | Eigege, Abel Evans, Darin S Noland, Gregory S Davies, Emmanuel Umaru, John Adelamo, Solomon E Mancha, Bulus King, Jonathan D Miri, Emmanuel S Okoeguale, Bridget Griswold, Emily P Richards, Jr, Frank O |
| description | Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States, Nigeria, after 8-12 years of annual albendazole-ivermectin treatment. A total of 7,131 first- and second-year primary school children (approximately 6-7 years old) were tested for LF antigen by immunochromatographic test (ICT) from May to June 2012. The target sample size of 1,692 was exceeded in each EU (range = 1,767-1,795). A total of 25 (0.4%) individuals were ICT positive, with the number of positives in each EU (range = 3-11) less than the TAS cutoff of 20, meaning that LF transmission had been reduced below sustainable levels. As a result, 3.5 million annual albendazole-ivermectin treatments were halted in 2013. Combined with the previous halt of MDA for LF in other parts of Plateau and Nasarawa, these are the first Nigerian states to stop LF MDA statewide. Posttreatment surveillance is ongoing to determine if LF transmission has been interrupted. |
| doi_str_mv | 10.4269/ajtmh.16-0843 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5590580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1924602713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-5bd56fb22d720f0dcdcbfe662a6d9ef767436722c3c781579a0bcec48e06234e3</originalsourceid><addsrcrecordid>eNpVkU9v1DAQxS0EokvhyBX5yIEU_4udXJCWhVKkpSBRztbEmWxcJfHWdhb1A_C9ydJSwckaz2_em9Ej5CVnZ0ro-i1c57E_47pglZKPyIorowuuVfmYrBhjoqi1NCfkWUrXjPFKcP6UnIjKqNqU9Yr82kSfMXqgOdDvOezpF0iJfojzjq7b0U8-5QjZh4l2IdLt7bjvl9LRcz_AMpZ8ohdwQPoecaJr13s8YEuv-hjmXR_mTL8NkBFmClNLLyFBhJ-wOC2f6Q299Luj-XPypIMh4Yv795T8OP94tbkotl8_fd6st4WTlclF2bSl7hohWiNYx1rXuqZDrQXotsbOaKOkNkI46UzFS1MDaxw6VSHTQiqUp-Tdne5-bkZsHU7LcYPdRz9CvLUBvP2_M_ne7sLBlmXNyootAq_vBWK4mTFlO_rkcBhgwjAny2uhNBOGywUt7lAXQ0oRuwcbzuwxOvsnOsu1PUa38K_-3e2B_puV_A021ZjW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1924602713</pqid></control><display><type>article</type><title>Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Eigege, Abel ; Evans, Darin S ; Noland, Gregory S ; Davies, Emmanuel ; Umaru, John ; Adelamo, Solomon E ; Mancha, Bulus ; King, Jonathan D ; Miri, Emmanuel S ; Okoeguale, Bridget ; Griswold, Emily P ; Richards, Jr, Frank O</creator><creatorcontrib>Eigege, Abel ; Evans, Darin S ; Noland, Gregory S ; Davies, Emmanuel ; Umaru, John ; Adelamo, Solomon E ; Mancha, Bulus ; King, Jonathan D ; Miri, Emmanuel S ; Okoeguale, Bridget ; Griswold, Emily P ; Richards, Jr, Frank O</creatorcontrib><description>Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States, Nigeria, after 8-12 years of annual albendazole-ivermectin treatment. A total of 7,131 first- and second-year primary school children (approximately 6-7 years old) were tested for LF antigen by immunochromatographic test (ICT) from May to June 2012. The target sample size of 1,692 was exceeded in each EU (range = 1,767-1,795). A total of 25 (0.4%) individuals were ICT positive, with the number of positives in each EU (range = 3-11) less than the TAS cutoff of 20, meaning that LF transmission had been reduced below sustainable levels. As a result, 3.5 million annual albendazole-ivermectin treatments were halted in 2013. Combined with the previous halt of MDA for LF in other parts of Plateau and Nasarawa, these are the first Nigerian states to stop LF MDA statewide. Posttreatment surveillance is ongoing to determine if LF transmission has been interrupted.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.16-0843</identifier><identifier>PMID: 28749759</identifier><language>eng</language><publisher>United States: The American Society of Tropical Medicine and Hygiene</publisher><subject>Albendazole - administration & dosage ; Albendazole - therapeutic use ; Anthelmintics - administration & dosage ; Anthelmintics - therapeutic use ; Antigens, Helminth - blood ; Child ; Chromatography, Affinity ; Elephantiasis, Filarial - epidemiology ; Elephantiasis, Filarial - prevention & control ; Humans ; Ivermectin - administration & dosage ; Ivermectin - therapeutic use ; Nigeria - epidemiology ; Population Surveillance</subject><ispartof>The American journal of tropical medicine and hygiene, 2017-09, Vol.97 (3), p.677-680</ispartof><rights>The American Society of Tropical Medicine and Hygiene 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-5bd56fb22d720f0dcdcbfe662a6d9ef767436722c3c781579a0bcec48e06234e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590580/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590580/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28749759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eigege, Abel</creatorcontrib><creatorcontrib>Evans, Darin S</creatorcontrib><creatorcontrib>Noland, Gregory S</creatorcontrib><creatorcontrib>Davies, Emmanuel</creatorcontrib><creatorcontrib>Umaru, John</creatorcontrib><creatorcontrib>Adelamo, Solomon E</creatorcontrib><creatorcontrib>Mancha, Bulus</creatorcontrib><creatorcontrib>King, Jonathan D</creatorcontrib><creatorcontrib>Miri, Emmanuel S</creatorcontrib><creatorcontrib>Okoeguale, Bridget</creatorcontrib><creatorcontrib>Griswold, Emily P</creatorcontrib><creatorcontrib>Richards, Jr, Frank O</creatorcontrib><title>Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States, Nigeria, after 8-12 years of annual albendazole-ivermectin treatment. A total of 7,131 first- and second-year primary school children (approximately 6-7 years old) were tested for LF antigen by immunochromatographic test (ICT) from May to June 2012. The target sample size of 1,692 was exceeded in each EU (range = 1,767-1,795). A total of 25 (0.4%) individuals were ICT positive, with the number of positives in each EU (range = 3-11) less than the TAS cutoff of 20, meaning that LF transmission had been reduced below sustainable levels. As a result, 3.5 million annual albendazole-ivermectin treatments were halted in 2013. Combined with the previous halt of MDA for LF in other parts of Plateau and Nasarawa, these are the first Nigerian states to stop LF MDA statewide. Posttreatment surveillance is ongoing to determine if LF transmission has been interrupted.</description><subject>Albendazole - administration & dosage</subject><subject>Albendazole - therapeutic use</subject><subject>Anthelmintics - administration & dosage</subject><subject>Anthelmintics - therapeutic use</subject><subject>Antigens, Helminth - blood</subject><subject>Child</subject><subject>Chromatography, Affinity</subject><subject>Elephantiasis, Filarial - epidemiology</subject><subject>Elephantiasis, Filarial - prevention & control</subject><subject>Humans</subject><subject>Ivermectin - administration & dosage</subject><subject>Ivermectin - therapeutic use</subject><subject>Nigeria - epidemiology</subject><subject>Population Surveillance</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU9v1DAQxS0EokvhyBX5yIEU_4udXJCWhVKkpSBRztbEmWxcJfHWdhb1A_C9ydJSwckaz2_em9Ej5CVnZ0ro-i1c57E_47pglZKPyIorowuuVfmYrBhjoqi1NCfkWUrXjPFKcP6UnIjKqNqU9Yr82kSfMXqgOdDvOezpF0iJfojzjq7b0U8-5QjZh4l2IdLt7bjvl9LRcz_AMpZ8ohdwQPoecaJr13s8YEuv-hjmXR_mTL8NkBFmClNLLyFBhJ-wOC2f6Q299Luj-XPypIMh4Yv795T8OP94tbkotl8_fd6st4WTlclF2bSl7hohWiNYx1rXuqZDrQXotsbOaKOkNkI46UzFS1MDaxw6VSHTQiqUp-Tdne5-bkZsHU7LcYPdRz9CvLUBvP2_M_ne7sLBlmXNyootAq_vBWK4mTFlO_rkcBhgwjAny2uhNBOGywUt7lAXQ0oRuwcbzuwxOvsnOsu1PUa38K_-3e2B_puV_A021ZjW</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Eigege, Abel</creator><creator>Evans, Darin S</creator><creator>Noland, Gregory S</creator><creator>Davies, Emmanuel</creator><creator>Umaru, John</creator><creator>Adelamo, Solomon E</creator><creator>Mancha, Bulus</creator><creator>King, Jonathan D</creator><creator>Miri, Emmanuel S</creator><creator>Okoeguale, Bridget</creator><creator>Griswold, Emily P</creator><creator>Richards, Jr, Frank O</creator><general>The American Society of Tropical Medicine and Hygiene</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201709</creationdate><title>Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria</title><author>Eigege, Abel ; Evans, Darin S ; Noland, Gregory S ; Davies, Emmanuel ; Umaru, John ; Adelamo, Solomon E ; Mancha, Bulus ; King, Jonathan D ; Miri, Emmanuel S ; Okoeguale, Bridget ; Griswold, Emily P ; Richards, Jr, Frank O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-5bd56fb22d720f0dcdcbfe662a6d9ef767436722c3c781579a0bcec48e06234e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Albendazole - administration & dosage</topic><topic>Albendazole - therapeutic use</topic><topic>Anthelmintics - administration & dosage</topic><topic>Anthelmintics - therapeutic use</topic><topic>Antigens, Helminth - blood</topic><topic>Child</topic><topic>Chromatography, Affinity</topic><topic>Elephantiasis, Filarial - epidemiology</topic><topic>Elephantiasis, Filarial - prevention & control</topic><topic>Humans</topic><topic>Ivermectin - administration & dosage</topic><topic>Ivermectin - therapeutic use</topic><topic>Nigeria - epidemiology</topic><topic>Population Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eigege, Abel</creatorcontrib><creatorcontrib>Evans, Darin S</creatorcontrib><creatorcontrib>Noland, Gregory S</creatorcontrib><creatorcontrib>Davies, Emmanuel</creatorcontrib><creatorcontrib>Umaru, John</creatorcontrib><creatorcontrib>Adelamo, Solomon E</creatorcontrib><creatorcontrib>Mancha, Bulus</creatorcontrib><creatorcontrib>King, Jonathan D</creatorcontrib><creatorcontrib>Miri, Emmanuel S</creatorcontrib><creatorcontrib>Okoeguale, Bridget</creatorcontrib><creatorcontrib>Griswold, Emily P</creatorcontrib><creatorcontrib>Richards, Jr, Frank O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eigege, Abel</au><au>Evans, Darin S</au><au>Noland, Gregory S</au><au>Davies, Emmanuel</au><au>Umaru, John</au><au>Adelamo, Solomon E</au><au>Mancha, Bulus</au><au>King, Jonathan D</au><au>Miri, Emmanuel S</au><au>Okoeguale, Bridget</au><au>Griswold, Emily P</au><au>Richards, Jr, Frank O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2017-09</date><risdate>2017</risdate><volume>97</volume><issue>3</issue><spage>677</spage><epage>680</epage><pages>677-680</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><abstract>Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States, Nigeria, after 8-12 years of annual albendazole-ivermectin treatment. A total of 7,131 first- and second-year primary school children (approximately 6-7 years old) were tested for LF antigen by immunochromatographic test (ICT) from May to June 2012. The target sample size of 1,692 was exceeded in each EU (range = 1,767-1,795). A total of 25 (0.4%) individuals were ICT positive, with the number of positives in each EU (range = 3-11) less than the TAS cutoff of 20, meaning that LF transmission had been reduced below sustainable levels. As a result, 3.5 million annual albendazole-ivermectin treatments were halted in 2013. Combined with the previous halt of MDA for LF in other parts of Plateau and Nasarawa, these are the first Nigerian states to stop LF MDA statewide. Posttreatment surveillance is ongoing to determine if LF transmission has been interrupted.</abstract><cop>United States</cop><pub>The American Society of Tropical Medicine and Hygiene</pub><pmid>28749759</pmid><doi>10.4269/ajtmh.16-0843</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9637 |
| ispartof | The American journal of tropical medicine and hygiene, 2017-09, Vol.97 (3), p.677-680 |
| issn | 0002-9637 1476-1645 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5590580 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Albendazole - administration & dosage Albendazole - therapeutic use Anthelmintics - administration & dosage Anthelmintics - therapeutic use Antigens, Helminth - blood Child Chromatography, Affinity Elephantiasis, Filarial - epidemiology Elephantiasis, Filarial - prevention & control Humans Ivermectin - administration & dosage Ivermectin - therapeutic use Nigeria - epidemiology Population Surveillance |
| title | Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T17%3A24%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Criteria%20to%20Stop%20Mass%20Drug%20Administration%20for%20Lymphatic%20Filariasis%20Have%20Been%20Achieved%20Throughout%20Plateau%20and%20Nasarawa%20States,%20Nigeria&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=Eigege,%20Abel&rft.date=2017-09&rft.volume=97&rft.issue=3&rft.spage=677&rft.epage=680&rft.pages=677-680&rft.issn=0002-9637&rft.eissn=1476-1645&rft_id=info:doi/10.4269/ajtmh.16-0843&rft_dat=%3Cproquest_pubme%3E1924602713%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1924602713&rft_id=info:pmid/28749759&rfr_iscdi=true |